Literature DB >> 32206602

Adrenal incidentaloma: cardiovascular and metabolic effects of mild cortisol excess.

Alan Kelsall1, Ahmed Iqbal1, John Newell-Price1.   

Abstract

In the vast majority of cases adrenal incidentalomas (AI) are benign adrenocortical adenomas. They are present in up to 10% of the population over 70 years, with incidence increasing with age. Mild cortisol excess (MCE) in the context of AI is defined as autonomous cortisol secretion (ACS) in the absence of the classical clinical features of Cushing's syndrome. MCE has been reported in up to at least one third of patients with AI. Numerous studies have shown that MCE in AI is associated with increased cardiovascular events and mortality, likely to be consequent upon both hemodynamic changes and inflammatory pathways, and a worse metabolic phenotype characterized by: pancreatic β-cell dysfunction, insulin resistance, visceral obesity and dyslipidemia. There is currently no level 3 evidence from large intervention randomized controlled trials to guide management of MCE in AI, and there is a lack of predictive tools to allow stratification to intervention of only those patients who would benefit in terms of improved metabolic and cardiovascular end-points. Here, we describe the mal-effects of cortisol on cardiovascular and metabolic tissues and discuss management strategies based on current largely observational data. 2020 Gland Surgery. All rights reserved.

Entities:  

Keywords:  Adrenal incidentalomas (AIs); adrenocorticotropic hormone (ACTH); autonomous cortisol secretion (ACS); mild cortisol excess (MCE); non-functioning adenoma (NFAI); overnight dexamethasone suppression test (ONDST)

Year:  2020        PMID: 32206602      PMCID: PMC7082271          DOI: 10.21037/gs.2019.11.19

Source DB:  PubMed          Journal:  Gland Surg        ISSN: 2227-684X


  65 in total

1.  Progressively increased patterns of subclinical cortisol hypersecretion in adrenal incidentalomas differently predict major metabolic and cardiovascular outcomes: a large cross-sectional study.

Authors:  Guido Di Dalmazi; Valentina Vicennati; Eleonora Rinaldi; Antonio Maria Morselli-Labate; Emanuela Giampalma; Cristina Mosconi; Uberto Pagotto; Renato Pasquali
Journal:  Eur J Endocrinol       Date:  2012-01-20       Impact factor: 6.664

Review 2.  Glucose Metabolism Abnormalities in Cushing Syndrome: From Molecular Basis to Clinical Management.

Authors:  Carla Scaroni; Marialuisa Zilio; Michelangelo Foti; Marco Boscaro
Journal:  Endocr Rev       Date:  2017-06-01       Impact factor: 19.871

Review 3.  Pathophysiology of dyslipidaemia in the metabolic syndrome.

Authors:  G D Kolovou; K K Anagnostopoulou; D V Cokkinos
Journal:  Postgrad Med J       Date:  2005-06       Impact factor: 2.401

4.  Beneficial metabolic effects of prompt surgical treatment in patients with an adrenal incidentaloma causing biochemical hypercortisolism.

Authors:  Iacopo Chiodini; Valentina Morelli; Antonio Stefano Salcuni; Cristina Eller-Vainicher; Massimo Torlontano; Francesca Coletti; Laura Iorio; Antonello Cuttitta; Angelo Ambrosio; Leonardo Vicentini; Fabio Pellegrini; Massimiliano Copetti; Paolo Beck-Peccoz; Maura Arosio; Bruno Ambrosi; Vincenzo Trischitta; Alfredo Scillitani
Journal:  J Clin Endocrinol Metab       Date:  2010-04-07       Impact factor: 5.958

5.  Management of the clinically inapparent adrenal mass ("incidentaloma").

Authors:  Melvin M Grumbach; Beverly M K Biller; Glenn D Braunstein; Karen K Campbell; J Aidan Carney; Paul A Godley; Emily L Harris; Joseph K T Lee; Yolanda C Oertel; Mitchell C Posner; Janet A Schlechte; H Samuel Wieand
Journal:  Ann Intern Med       Date:  2003-03-04       Impact factor: 25.391

6.  Impact of hypercortisolism on skeletal muscle mass and adipose tissue mass in patients with adrenal adenomas.

Authors:  Danae A Delivanis; Nicole M Iñiguez-Ariza; Muhammad H Zeb; Michael R Moynagh; Naoki Takahashi; Travis J McKenzie; Melinda A Thomas; Charalambos Gogos; William F Young; Irina Bancos; Venetsana Kyriazopoulou
Journal:  Clin Endocrinol (Oxf)       Date:  2017-11-29       Impact factor: 3.478

7.  Carotid intima media thickness is increased and associated with morning cortisol in subjects with non-functioning adrenal incidentaloma.

Authors:  Serkan Yener; Sinan Genc; Baris Akinci; Mustafa Secil; Tevfik Demir; Abdurrahman Comlekci; Senem Ertilav; Sena Yesil
Journal:  Endocrine       Date:  2009-03-10       Impact factor: 3.633

8.  Removal of visceral fat prevents insulin resistance and glucose intolerance of aging: an adipokine-mediated process?

Authors:  Ilan Gabriely; Xiao Hui Ma; Xiao Man Yang; Gil Atzmon; Michael W Rajala; Anders H Berg; Phillip Scherer; Luciano Rossetti; Nir Barzilai
Journal:  Diabetes       Date:  2002-10       Impact factor: 9.461

9.  Visceral fat accumulation and postdexamethasone serum cortisol levels in patients with adrenal incidentaloma.

Authors:  Miguel Debono; Anna Prema; Timothy J B Hughes; Matthew Bull; Richard J Ross; John Newell-Price
Journal:  J Clin Endocrinol Metab       Date:  2013-04-30       Impact factor: 5.958

10.  Mifepristone reduces insulin resistance in patient volunteers with adrenal incidentalomas that secrete low levels of cortisol: a pilot study.

Authors:  Miguel Debono; Rita Chadarevian; Richard Eastell; Richard J Ross; John Newell-Price
Journal:  PLoS One       Date:  2013-04-05       Impact factor: 3.240

View more
  2 in total

1.  Modulation of Dyslipidemia Markers Apo B/Apo A and Triglycerides/HDL-Cholesterol Ratios by Low-Carbohydrate High-Fat Diet in a Rat Model of Metabolic Syndrome.

Authors:  Abrar Alnami; Abdulhadi Bima; Aliaa Alamoudi; Basmah Eldakhakhny; Hussein Sakr; Ayman Elsamanoudy
Journal:  Nutrients       Date:  2022-05-01       Impact factor: 6.706

2.  Intratumoral steroid profiling of adrenal cortisol-producing adenomas by liquid chromatography- mass spectrometry.

Authors:  James P Teuber; Kazutaka Nanba; Adina F Turcu; Xuan Chen; Lili Zhao; Tobias Else; Richard J Auchus; William E Rainey; Juilee Rege
Journal:  J Steroid Biochem Mol Biol       Date:  2021-06-02       Impact factor: 5.011

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.